271P Efficacy and safety of cemiplimab in the treatment of cutaneous squamous cell carcinoma in patients with dystrophic epidermolysis bullosa

March 1, 2026ESMO rare cancers.Open Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to assess the efficacy and safety of cemiplimab in patients with cutaneous squamous cell carcinoma and dystrophic epidermolysis bullosa.
Analyzed patient records from Russian clinics treating cutaneous squamous cell carcinoma
Measured objective response rates, progression-free survival, and overall survival
Employed Cox regression to identify factors affecting survival outcomes
Objective response rate was 23% among evaluable patients
Median progression-free survival was 4.1 months
Median overall survival was 19.9 months
Lack of response significantly worsened overall survival
Female sex was associated with improved overall survival

Answers are grounded in this paper and cite their sources.

Evaluates the efficacy of cemiplimab treatment in cutaneous squamous cell carcinoma, indicating needs for improved approaches.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Paterczyk et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share